Walleye Capital LLC Buys New Position in CeriBell (NASDAQ:CBLL)

Walleye Capital LLC acquired a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 58,800 shares of the company's stock, valued at approximately $1,522,000. Walleye Capital LLC owned 0.16% of CeriBell as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in CeriBell in the fourth quarter valued at about $32,000. Summit Investment Advisors Inc. bought a new stake in CeriBell during the 4th quarter worth approximately $33,000. PNC Financial Services Group Inc. acquired a new stake in CeriBell during the 4th quarter valued at $47,000. Corebridge Financial Inc. bought a new position in CeriBell in the 4th quarter valued at $158,000. Finally, Wells Fargo & Company MN acquired a new position in CeriBell in the fourth quarter worth $167,000.

CeriBell Stock Down 2.5 %

Shares of CeriBell stock traded down $0.39 during trading on Friday, reaching $15.11. 70,734 shares of the company were exchanged, compared to its average volume of 271,563. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75. The business's 50-day simple moving average is $19.78.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. Analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Activity

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of the business's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the transaction, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at approximately $11,211,694.02. The trade was a 0.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 24,700 shares of company stock valued at $372,434 in the last quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on CBLL shares. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH initiated coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.